Francisco Partners Is Taking Weave Communications Private for $650M. Here Is What That Means for Small-Cap Software Investors.

TL;DR: Francisco Partners announced on August 18, 2026 that it will acquire Weave Communications (NYSE: WEAV) in an all-cash deal worth roughly $650 million, or $7.40 per share — a 34% premium to Weave's August 17 closing price of $5.52. Weave's board unanimously approved the transaction. The deal is expected to close in Q4 2026 and represents one of the cleaner examples of the ongoing small-cap software take-private wave reshaping public markets.

The Deal: What Francisco Partners Is Actually Buying

Weave Communications builds customer communication software for small and mid-sized healthcare businesses , dental offices, optometry practices, veterinary clinics. The platform bundles phone systems, two-way texting, online scheduling, payment processing, and patient messaging into a single tool. That combination matters because it creates real lock-in. A dental office that processes payments through Weave, texts appointment reminders through Weave, and manages its reviews through Weave does not switch vendors easily. Francisco Partners knows this. They are not buying a turnaround story. They are buying a sticky revenue base at a price public markets suppressed below intrinsic value.

The numbers tell the story clearly. Weave posted $239 million in FY2025 revenue, up 17% from FY2024. Q1 FY2026 continued that pace at $65.5 million, again up 17% year-over-year. The company serves more than 40,000 customer locations across the United States. In 2025, Weave also acquired TrueLark Inc., an AI startup focused on automated patient communication , giving Francisco Partners an AI layer to monetize without needing to build it from scratch.

The $7.40 per share price deserves context. Weave IPO'd at $24.00 per share in November 2021 and hit an all-time high of $22.40 shortly after. Then the rate cycle hit, SaaS multiples compressed across the board, and Weave never recovered its IPO price in the public markets. Francisco Partners stepped in at $7.40 , a 69% discount to the IPO price , and handed long-term public investors a 34% overnight premium that still left them underwater from their 2021 entry. That is the fundamental tension accredited investors need to sit with: the premium feels like a win, but the buyer is the one who actually captures the long-term value creation.

Weave CEO Brett White and Board Chair Stuart C. Harvey Jr. signed off unanimously. Jefferies LLC advised Weave; Kirkland and Ellis LLP advised Francisco Partners. Francisco Partners' Co-President Ezra Perlman and Principal Nick Nelson led the acquisition.

Francisco Partners' Pattern: Healthcare Tech Is the Play

Francisco Partners has raised more than $75 billion in capital and invested in over 500 technology companies since founding in 1999. HEC Paris and Dow Jones ranked the firm the number-one global large buyout performer in 2024. They are not generalist PE. They have a specific thesis, and the Weave deal confirms it: buy vertical software with embedded payments, a large SMB customer base, and a unit economics profile that the public markets are mispricing because of AI disruption fears.

The AdvancedMD acquisition is the clearest precedent. In November 2024, Francisco Partners acquired AdvancedMD from Global Payments for $1.125 billion. AdvancedMD provides practice management and electronic health records software to physician practices , another vertical healthcare SaaS business with sticky customers and embedded billing. Global Payments was shedding non-core assets. Francisco Partners stepped in at a distressed-seller valuation. The parallel to Weave is direct: Francisco Partners is building a healthcare technology portfolio of vertically integrated, payments-enabled SaaS companies that it can run outside the scrutiny of quarterly earnings calls.

The private setting matters for operations. When you take a software company private, you can invest in product, sales, and headcount without Wall Street penalizing you for a quarter of elevated costs. You can acquire smaller competitors without an earnings-per-share dilution headline. You can renegotiate vendor contracts and consolidate operations on your own timeline. Francisco Partners has done this repeatedly across healthcare IT, financial technology, and enterprise software. Weave fits the pattern.

The Broader 2025-2026 Software Take-Private Wave

Weave is not an isolated event. The data on software take-privates across 2025 and into 2026 is striking. According to ION Analytics and Mergermarket data published in March 2026, North American software exit volume jumped 42% to $96.5 billion in 2025. AlixPartners, led by TMT practice head Mario Ribera, projects software M&A will increase another 40% year-over-year as PE firms continue rolling up sub-scale names at compressed valuations.

The Integral Ad Science deal is another reference point. Novacap took Integral Ad Science private in December 2025 for $1.9 billion at a sub-10x EBITDA multiple , a multiple that would have seemed impossible for a profitable ad tech SaaS company at the 2021 peak. Axios Pro reported in April 2026 that roughly 90% of current take-private candidates identified in PitchBook data are software stocks. The setup is consistent: rates compressed multiples, AI disruption fears created sentiment overhangs, and PE firms with dry powder moved in.

The structural driver is simple. Between 2020 and 2022, hundreds of SaaS companies went public at revenue multiples of 20x to 40x. Rates rose. Growth-at-any-cost gave way to profitability requirements. Multiples collapsed to 3x to 8x revenue for many mid-tier names. PE firms, sitting on committed capital that needs deployment, looked at those multiples against the underlying business fundamentals and saw an opportunity. The public markets, spooked by AI substitution risk and slower growth rates, kept prices down. PE wrote checks.

Selected 2025-2026 Software Take-Privates

Company	Acquirer	Deal Value	Close	Premium
Weave Communications (WEAV)	Francisco Partners	$650M	Q4 2026 (expected)	34%
Integral Ad Science (IAS)	Novacap	$1.9B	Dec 2025	Sub-10x EBITDA
AdvancedMD	Francisco Partners	$1.125B	Nov 2024	Distressed seller

How I Would Screen for the Next Weave

I want to be honest with you about what you can and cannot do here. PE firms run proprietary deal processes. They have access to management teams, data rooms, and channel checks that you do not have. The information asymmetry is real, and I am not going to pretend you can neutralize it entirely. What you can do is screen public data for companies that fit the profile PE firms are actively pursuing, build a position before a deal is announced, and accept that you might hold for months or years before anything happens , or nothing happens at all.

The signal set is consistent across the deals I track. First, look for revenue growth between 10% and 25% annually in vertical SaaS , fast enough to be interesting, slow enough that the public market has stopped rewarding the stock. Second, find companies with a price-to-revenue multiple below 4x and net revenue retention above 100%. High NRR (net revenue retention , a measure of how much existing customers expand their spending) tells you the product is sticky. A low multiple tells you the market is not paying for that stickiness. Third, look for companies with embedded payments or workflow integrations that make switching painful. Fourth, find a market cap below $1 billion with a float small enough that a PE firm can acquire without needing to fight a competing bidder. Weave checked every box before the announcement.

Specific sectors I watch right now: dental and veterinary practice management software, independent pharmacy software, specialty contractor field service software, and community bank core technology. These are all markets with fragmented small-business customers, high switching costs, and incumbent players that public markets are discounting because they are not building large language models.

The Risks You Need to Take Seriously

Three risks matter most here, and I want to name them plainly. The first is the upside transfer risk. When a PE firm takes a healthy software company private at a suppressed multiple, the public shareholders get the premium but not the recovery upside. If Francisco Partners grows Weave's revenue from $239 million to $400 million over three years and exits at a 6x revenue multiple, they will realize a return that Weave's long-term public shareholders never see. The 34% premium looks good on announcement day. The five-year IRR looks much better to Francisco Partners.

The second risk is timing. You can identify a perfect take-private candidate and hold it for three years with no deal. Management may not want a deal. The company's controlling shareholder may block a transaction. PE may find a better-priced target. Capital markets may improve enough that the company decides to grow publicly again. Take-private theses require patience and position sizing discipline , never a concentrated bet on a single name.

The third risk is your own information disadvantage. PE firms spend months doing diligence before a deal is announced. They talk to customers, former employees, and competitors. They model the business with data you will never see. If you are building a position based on public filings and earnings calls alone, you are working with a subset of the information driving the deal. That does not make the strategy invalid, but it means your conviction needs to be calibrated accordingly. Size these positions as part of a diversified small-cap software basket, not as single-stock conviction bets.

Frequently Asked Questions

Why is Francisco Partners paying only $7.40 per share when Weave IPO'd at $24.00?

The IPO price reflected 2021 valuations, when public markets were paying 20x to 40x revenue for SaaS companies with high growth rates regardless of profitability. Rates rose sharply in 2022 and 2023, multiple expansion reversed, and Weave's stock never recovered its IPO price even as the underlying business continued growing. Francisco Partners is buying the company at a multiple that reflects current public market sentiment, not the fundamental value of a 40,000-customer vertical SaaS business with embedded payments and 17% revenue growth. That gap between sentiment and fundamentals is exactly what PE firms look for.

What happens to Weave shareholders who do not want to sell at $7.40?

In an all-cash merger approved by the board, shareholders who vote against the deal can pursue appraisal rights under Delaware law , a legal process where a court determines the fair value of the shares. That process is expensive, slow, and uncertain; most individual shareholders accept the deal price. Once the transaction closes, Weave common stock is delisted from the NYSE and shareholders who held through the record date receive $7.40 per share in cash. There is no mechanism for public shareholders to participate in Weave's future growth once the company is private.

Is this the kind of deal accredited investors can participate in directly?

The Francisco Partners acquisition of Weave is a closed PE fund transaction, not an opportunity open to individual accredited investors. You could have participated by holding WEAV shares in the public market before the deal announcement and receiving the merger consideration at close. The way accredited investors access Francisco Partners-style deal flow directly is through commitments to PE funds, co-investment programs with established fund managers, or through vehicles like BDCs (business development companies) and interval funds that invest in private credit alongside PE buyouts , all of which have their own fees, liquidity constraints, and minimums that you need to evaluate carefully.

How do I find small-cap software companies that fit the take-private profile?

Start with stock screeners filtering for U.S.-listed software companies with market caps between $200 million and $1.5 billion, revenue growth above 10% year-over-year, price-to-sales ratios below 4x, and net revenue retention above 100% where disclosed. SEC filings are your friend , read the risk factors and business description sections of 10-K filings for language about "mission-critical" workflows, embedded payments, and switching costs. Then cross-reference those names against recent PE activity in adjacent sectors, because firms like Francisco Partners, Thoma Bravo, Vista Equity, and Symphony Technology Group tend to buy within categories where they already have portfolio companies and operational knowledge.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.